Health breakthroughs and money matters, in plain words

Home » INTerpath-001 trial shows intismeran cuts melanoma recurrence risk 42%

INTerpath-001 trial shows intismeran cuts melanoma recurrence risk 42%

By

–

INTerpath-001 trial shows intismeran cuts melanoma recurrence risk 42%

Adding a personalized mRNA therapy to Keytruda cut the risk of melanoma coming back, or of death, by 42% compared with Keytruda alone. Georgina V. Long of Melanoma Institute Australia presented the phase 3 INTerpath-001 results on October 24 at the European Society for Medical Oncology (ESMO) Congress. Merck and Moderna, the companies behind the therapy, intismeran autogene, say it is the first phase 3 study to show a clinically meaningful gain over Keytruda in patients whose melanoma has been surgically removed.

How the trial was run

The study enrolled 1,137 patients with completely resected stage IIB to IV cutaneous melanoma. Two thirds, 757 patients, received intismeran plus Keytruda (pembrolizumab). The other 380 got placebo plus Keytruda. Neither patients nor doctors knew who had which.

Intismeran is built from each patient’s own tumor. Sequencing picks out the mutations unique to that cancer, and the resulting mRNA codes for up to 34 neoantigens meant to train the immune system to attack. Patients received it as an intramuscular dose every three weeks, up to nine doses, while Keytruda went in intravenously every six weeks.

What the numbers show

At a data cutoff of June 30, 2026, median follow-up was 24.6 months. The hazard ratio for recurrence-free survival was 0.58 (95% CI, 0.45 to 0.75). Two years out, 82.2% of patients on the combination had no recurrence, against 70.0% on Keytruda alone. Distant metastasis-free survival also improved: a hazard ratio of 0.62, with two-year rates of 88.5% versus 80.2%.

Timing matters here. In the first six months the two arms looked alike, with a recurrence hazard ratio of 0.99. After that point it dropped to 0.42. The benefit appeared across disease stages and age groups, though several smaller subgroups had confidence intervals that crossed 1.

Overall survival is the open question. The data are immature, and the hazard ratio of 0.77 (95% CI, 0.45 to 1.31) did not reach the prespecified significance boundary. Follow-up continues.

Safety

Grade 3 to 5 treatment-related adverse events were close between arms, at 14.2% with the combination and 13.4% with Keytruda alone. Two patients on the combination died of treatment-related causes, both attributed to pembrolizumab and none to intismeran. Fever, injection site pain and fatigue were the most common complaints, and investigators called them low grade and transient. Even so, 14.0% on the combination stopped a study drug because of side effects, versus 8.7% on Keytruda alone.

The market’s verdict

The science landed badly with investors. The data leaked through an oncology website two days before the ESMO embargo lifted, and reports said Moderna shares fell about 25%, wiping roughly $24 billion from its market value, while Merck slipped almost 1%. Analysts cited in coverage said the distant-metastasis result fell short of high expectations, and that investors doubted whether success would extend beyond melanoma. The companies are testing intismeran in nine phase 2 and 3 trials, including three phase 3 studies in non-small cell lung cancer.

The results have been accepted by The New England Journal of Medicine. Merck and Moderna say they are engaging with regulators, and intismeran is not approved anywhere. It has been tested only in fully resected melanoma, and whether it helps patients live longer is not yet known. Patients should ask their oncologist whether a clinical trial or an approved treatment fits their case.

Sources

Photo: Julia Koblitz / Unsplash (Unsplash License)

Get breaking stories first on our Telegram channel.

More stories by

Most read

Health & Medicine

Personal Finance

Cancer News

Health News